Last reviewed · How we verify

Topical IBU twice daily

Pfizer · Phase 3 active Small molecule

Topical IBU twice daily is a NSAID Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Relief of pain and inflammation associated with minor sprains, strains, and bruises.

Topical IBU works by reducing pain and inflammation at the site of application.

Topical IBU works by reducing pain and inflammation at the site of application. Used for Relief of pain and inflammation associated with minor sprains, strains, and bruises.

At a glance

Generic nameTopical IBU twice daily
SponsorPfizer
Drug classNSAID
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

It does this by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation. Topical IBU is a nonsteroidal anti-inflammatory drug (NSAID) that is applied directly to the skin to provide localized relief from pain and inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical IBU twice daily

What is Topical IBU twice daily?

Topical IBU twice daily is a NSAID drug developed by Pfizer, indicated for Relief of pain and inflammation associated with minor sprains, strains, and bruises.

How does Topical IBU twice daily work?

Topical IBU works by reducing pain and inflammation at the site of application.

What is Topical IBU twice daily used for?

Topical IBU twice daily is indicated for Relief of pain and inflammation associated with minor sprains, strains, and bruises.

Who makes Topical IBU twice daily?

Topical IBU twice daily is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is Topical IBU twice daily in?

Topical IBU twice daily belongs to the NSAID class. See all NSAID drugs at /class/nsaid.

What development phase is Topical IBU twice daily in?

Topical IBU twice daily is in Phase 3.

What are the side effects of Topical IBU twice daily?

Common side effects of Topical IBU twice daily include Skin irritation.

Related